Can-Fite BioPharma (CANF) EBT (2014 - 2023)

Can-Fite BioPharma (CANF) has 10 years of EBT data on file, last reported at -$1.8 million in Q4 2023.

• For the quarter ending Q4 2023, EBT fell 55.16% year-over-year to -$1.8 million; the trailing twelve-month figure through Dec 2023 stood at -$8.2 million (changed 0.0% YoY), and the FY2025 full-year result was -$9.8 million, down 24.72% from the prior year.
• EBT was -$1.8 million for Q4 2023 at Can-Fite BioPharma, up from -$1.9 million in the prior quarter.
• In the past five years, EBT ranged from a high of $1.6 million in Q1 2019 to a low of -$6.2 million in Q2 2019.
• A 5-year average of -$2.5 million and a median of -$2.4 million in 2022 frame the typical range for EBT.
• Across the five-year window, EBT slumped 17169.23% in 2019 and jumped 70.66% in 2022, its largest moves.
• Can-Fite BioPharma's EBT stood at -$2.1 million in 2019, then plunged by 69.03% to -$3.6 million in 2020, then dropped by 13.37% to -$4.0 million in 2021, then soared by 70.66% to -$1.2 million in 2022, then sank by 55.16% to -$1.8 million in 2023.
• Per Business Quant data, the three most recent EBT figures were -$1.8 million in Q4 2023, -$1.9 million in Q3 2023, and -$1.8 million in Q2 2023.